DeLIVER Trial Begins for Metavention’s iRF Denervation System to Treat Type 2 Diabetes

February 17, 2021—Metavention, Inc. announces the initiation of FDA-approved DeLIVER clinical investigation for the company’s intravascular integrated radiofrequency (iRF) denervation system to determine safety in patients with type 2 diabetes mellitus.

Metavention’s iRF denervation system is designed to be a one-time transcatheter procedure using radiofrequency energy to inhibit overactive sympathetic nerve signaling to the liver, thereby improving overall glucose control. The iRF denervation system is an investigational device and is limited by United States law to investigational use, advised the company.

Physicians at HSHS St. John’s Hospital in Springfield, Illinois, treated the first patient in the United States DeLIVER study.

“We are excited to be participating in this groundbreaking, minimally invasive treatment for patients with type 2 diabetes,” commented Krishna Rocha-Singh, MD, in the company’s announcement. “There remains a substantial unmet clinical need for improved treatment options in the management of type 2 diabetes. The prospect of adding an endovascular therapy as an adjunct to the care of this challenging patient population is compelling and exciting.” Dr. Rocha-Singh is Chief Scientific Officer of the Prairie Heart Institute at HSHS St. John’s Hospital.